Abstract
The 3435C-->T polymorphism at the multidrug resistance gene 1 (MDR1) was examined in 74 patients with human immunodeficiency virus who initiated atazanavir therapy. The MDR1 genotype distribution at position 3435 was 28% CC, 45% CT, and 27% TT. Plasma levels of atazanavir were significantly higher in patients with genotype CC than in those with CT or TT, and bilirubin levels correlated with atazanavir concentrations.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / blood
-
Anti-HIV Agents / therapeutic use
-
Atazanavir Sulfate
-
CD4 Lymphocyte Count
-
Female
-
Genes, MDR / genetics*
-
Genetic Predisposition to Disease
-
Genotype
-
HIV Infections / drug therapy
-
HIV-1
-
Humans
-
Hyperbilirubinemia / blood
-
Hyperbilirubinemia / chemically induced*
-
Male
-
Middle Aged
-
Odds Ratio
-
Oligopeptides / adverse effects*
-
Oligopeptides / blood*
-
Oligopeptides / therapeutic use
-
Polymorphism, Genetic*
-
Pyridines / adverse effects*
-
Pyridines / blood*
-
Pyridines / therapeutic use
-
RNA, Viral / blood
-
Risk Factors
-
Viral Load
Substances
-
Anti-HIV Agents
-
Oligopeptides
-
Pyridines
-
RNA, Viral
-
Atazanavir Sulfate